Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for idiopathic pulmonary fibrosis into late-stage clinical testing.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life ...

The UK government will contribute up to £50 million of new investment into the scheme, with Lilly contributing up to £35 ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...